Decongestant Market

Decongestant Market, By Type of Decongestant (Oral Decongestants, Nasal Decongestants:), By Formulation (Tablets, Capsules, Syrups, Nasal Sprays, Drops, Inhalers), By Mode of Action (Alpha-Adrenergic Agonists, Vasoconstrictors, Others), By Application (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Sinusitis, Nasal Congestion, Cold and Flu, Others, By Distribution Channel (Over-the-Counter (OTC) Sales, Prescription-based Sales), By Age Group (Pediatric Population, Adult Population), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

A decongestant is a medicine which relieves nasal congestion and helps someone who has a cold to breathe more easily. Decongestants help ease a blocked or a stuffy nose and provide short-term relief for a blocked or a stuffy nose (nasal congestion). They work by reducing the swelling of the blood vessels in the nose. Decongestant nasal drops relieve the breathing problems caused by colds and flu. Tablets or nose drops containing a decongestant can be used to treat blocked noses. This helps to open up the airways. Thus, there is an increase in demand for decongestants worldwide.

Market Dynamics:

Increasing incidence of seasonal and perennial allergic rhinitis, rising prevalence of sinusitis, rise in demand for safe and effective decongestants (tablets, capsules, syrups, nasal sprays, drops, and inhalers, growing geriatric population, and introduction of novel products in the market are major factors expected to propel growth of the global decongestant market.

For instance, in June 2021, the Food & Drug Administration (FDA) approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis for adults and children six years of age and older.

Moreover, in July 2022, Dr Reddy's Laboratories launched an over-the-counter generic medication for relief from both nasal and sinus congestion due to colds or allergies. The company also launch Fexofenadine HCI 180mg and Pseudoephedrine HCI 240mg extended release tables in the U.S.

Key features of the study:

This report provides in-depth analysis of the global decongestant market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global decongestant market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include Mylan N.V., Church & Dwight Co., Inc., Perrigo Company plc, Procter & Gamble Co., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group plc, and Sandoz International GmbH (Novartis subsidiary), among others.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

The global decongestant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global decongestant market.

Detailed Segmentation:

By Type of Decongestant:

Oral Decongestants:

Pseudoephedrine

Phenylephrine

Others

Nasal Decongestants:

Oxymetazoline

Xylometazoline

Phenylephrine

Naphazoline

Others

By Formulation:

Tablets

Capsules

Syrups

Nasal Sprays

Drops

Inhalers

By Mode of Action:

Alpha-Adrenergic Agonists

Vasoconstrictors

Others

By Application:

Seasonal Allergic Rhinitis

Perennial Allergic Rhinitis

Sinusitis

Nasal Congestion

Cold and Flu

Others

By Distribution Channel:

Over-the-Counter (OTC) Sales

Prescription-based Sales

By Age Group:

Pediatric Population

Adult Population

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Company Profiles:

Mylan N.V.

Church & Dwight Co., Inc.

Perrigo Company plc

Procter & Gamble Co.

Bayer AG

Sanofi S.A.

Novartis AG

GlaxoSmithKline plc

Pfizer Inc.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Prestige Consumer Healthcare Inc.

Reckitt Benckiser Group plc

Sandoz International GmbH (Novartis subsidiary)